HIGH Altitude CArdiovascular REsearch Latin America Population Study

checkorphan
Learn more about:
Acute mountain sickness
Related Clinical Trial
Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD HIGH Altitude CArdiovascular REsearch Latin America Population Study Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

HIGH Altitude CArdiovascular REsearch Latin America Population Study

Official Title

HIGH Altitude CArdiovascular REsearch Latin America Population Study

Brief Summary

      High blood pressure (BP) is one of the principal cardiovascular risk factors. While BP levels
      and hypertension prevalence are well characterized in many populations, information on BP and
      on cardiovascular risk profile in high altitude inhabitants is limited and frequently
      contradictory, especially in the large highland populations of South America. The information
      on the effects of permanent high altitude exposure on cardiovascular variables including BP
      may be relevant in the light of the known BP-increasing effect of acute exposure to high
      altitude hypoxia. This information may have practical implications for millions of people
      living at elevated altitudes in Asia, South America and Africa.

      The inconclusive epidemiological evidence on BP and cardiovascular risk in high altitude
      dwellers may be the result of several factors, among them: 1) confounding by genetic and
      socio-economic factors; 2) imperfect methods of BP evaluation, in particular lack of data on
      ambulatory and home BP (both methods considered superior to conventional clinic BP in the
      assessment of exposure to high BP).

      On this background, the general aim of the study is to compare blood pressure levels and
      cardiovascular risk profile among population-based samples of subjects residing in Peruvian
      communities living at different altitudes.

Study Type

Observational

Primary Outcome

Difference in 24 h ambulatory systolic BP between lowlanders and highlanders.

Secondary Outcome

 Differences in 24 h DBP, daytime and night-time systolic and diastolic BP between lowlanders and highlanders

Condition

Hypertension

Intervention

Exposure to high altitude

Study Arms / Comparison Groups

 Lowlanders
Description:  People living at low (<1500 m) altitude

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Other

Estimated Enrollment

900

Start Date

January 26, 2021

Completion Date

December 2022

Primary Completion Date

August 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Adult (>18 years) male and female subjects;

          -  Highlanders: permanence at high (>2500 m) altitude;

          -  Lowlanders: permanence at low (<1500 m) altitude;

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Lowlanders who over 3 months preceding inclusion in the study spent considerable (> 7
             consecutive days) amount of time at altitudes above 1500 m;

          -  Highlanders who over 3 months preceding inclusion in the study spent considerable (>7
             consecutive days) amount of time at altitudes below 2500 m;

          -  Subjects cognitively incapable of providing informed consent or responding to a
             questionnaire

          -  Physical disability that would prevent study assessments from being performed

          -  Active pulmonary tuberculosis

          -  Pregnancy

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Gianfranco Parati, MD, +39 02 619112714, [email protected]

Location Countries

Peru

Location Countries

Peru

Administrative Informations

NCT ID

NCT04751292

Organization ID

09A921

Responsible Party

Sponsor

Study Sponsor

Istituto Auxologico Italiano

Collaborators

 Universidad Peruana Cayetano Heredia

Study Sponsor

Gianfranco Parati, MD, Principal Investigator, Istituto Auxologico Italiano

Verification Date

May 2021